ATR
AptarGroup, Inc.122.83
+0.50+0.41%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details transitory margin fixes
Q&A clarified Q4 margin dips as transitory, with Beauty hit by environmental upgrades and a supplier fire, Closures by maintenance backlog—both easing sharply in Q1 for sequential gains. Emergency medicine's $65 million 2026 headwind skews 70/30 to H1, but H2 margins should dominate via productivity north of $100 million and volume. Injectables eyed for high-single/low-double-digit growth, beyond GLP-1 tens of millions. NARCAN destocking met expectations; long-term low-mid single-digits from new baseline. Fixes are transitory. Management tone stayed confident on Pharma momentum ex-EM; watch Beauty recovery, cough/cold traction.
Key Stats
Market Cap
8.09BP/E (TTM)
19.72Basic EPS (TTM)
6.23Dividend Yield
0.01%Recent Filings
8-K
CEO succession planned
AptarGroup announced CEO Stephan Tanda's retirement effective September 1, 2026, appointing Pharma President Gael Touya as successor on that date. Tanda stays on as strategic advisor and board member through year-end, ensuring smooth handover. Touya's deal features $1.06M base, 120% target bonus, 500% LTI. Leadership continuity locked in.
10-K
FY2025 results
AptarGroup posted FY2025 net sales of $3.78B, up 5% reported and 2% core, with Pharma (46% of sales) accelerating to 3% core growth on 11% injectables and 5% prescription drug gains, while Beauty (35%) and Closures (19%) posted 2% and 1% core respectively amid softer F&F demand. Q4 saw $175M in aggressive buybacks under the $500M authorization, capping 32 years of dividend hikes at $1.83/share. Operating margins slipped to 13.3% on mix shift and inefficiencies, yet net income rose 5% to $393M ($5.89 diluted EPS). Debt climbed to $1.48B post-$600M notes issuance, but net debt/net capital stayed tame at 28.6% with $402M cash. Q1 2026 EPS guide: $1.13-$1.21 (ex-items). Tariffs threaten supply costs.
8-K
Q4 sales +14%, profits dip
AptarGroup reported Q4 sales up 14% to $963M with core sales +5% across all segments, yet net income fell 26% to $74M due to product mix and higher production costs—adjusted EPS hit $1.25. Full-year sales rose 5% to $3.78B, EPS up 7% to $5.89. Board approved $600M share repurchase authorization. Q1 2026 adjusted EPS guided $1.13-$1.21.
8-K
AptarGroup issues $600M notes
AptarGroup completed a $600 million public offering of 4.750% senior notes due March 30, 2031, on November 20, 2025. The unsecured notes pay interest semi-annually starting March 30, 2026, with make-whole redemption before February 28, 2031, and par thereafter. Holders can force repurchase at 101% upon a change of control. Indenture covenants limit liens and mergers.
10-Q
Q3 FY2025 results
AptarGroup posted Q3 net sales of $961M, up 6% y/y, with core growth of 1% (derived) fueled by Pharma volumes yet tempered by Beauty softness; operating income dipped to $137M from $138M while diluted EPS jumped 30% to $1.92 on a $27M BTY remeasurement gain. YTD sales rose 3% to $2.8B, operating income up 5% to $395M (derived), and EPS climbed 17% to $4.75 versus prior year, reconciling to 67K diluted shares. Cash swelled to $257M amid $386M operating cash flow, though FCF fell to $206M after $184M capex; net debt edged to 25% of capital with revolver room aplenty. Closed BTY in July 2025 for $36.6M cash, booking $72M goodwill and $21M intangibles over 13 years average life. Litigation clouds IP protection.
IPO
Website
Employees
Sector
Industry
ABT
Abbott Laboratories
126.86-1.61
ATRC
AtriCure, Inc.
41.08+0.04
AVTR
Avantor, Inc.
11.20-0.08
BAX
Baxter International Inc.
19.05-0.48
COSM
Cosmos Health Inc.
0.50+0.09
RVP
Retractable Technologies, Inc.
0.82-0.01
SHTPY
-
7.65+0.00
STVN
Stevanato Group S.p.A.
20.89-0.41
UFPT
UFP Technologies, Inc.
217.74-0.08
WST
West Pharmaceutical Services, I
266.44-5.42